Johnson & Johnson (JNJ) Earnings and revenue growth
- Revenue change · 12 months vs previous quarter: Value 1.63%; Formula and calculation Rolling 12-month amount / previous row rolling 12-month amount (2026-03-29) − 1. Period ending 2026-06-28..
- Diluted EPS change · 12 months vs previous quarter: Value (m); Formula and calculation Rolling 12-month amount / previous row rolling 12-month amount (2026-03-29) − 1. Period ending 2026-06-28..
- Net income change · 12 months vs previous quarter: Value -0.01%; Formula and calculation Rolling 12-month amount / previous row rolling 12-month amount (2026-03-29) − 1. Period ending 2026-06-28..
Earnings and revenue growth
Overview →Financial period ending 2026-06-28; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Revenue change · 12 months vs previous quarter | 1.63% | Rolling 12-month amount / previous row rolling 12-month amount (2026-03-29) − 1. Period ending 2026-06-28. ($97.93B ÷ $96.36B − 1) × 100 ≈ 1.63% |
| Diluted EPS change · 12 months vs previous quarter | (m) | Rolling 12-month amount / previous row rolling 12-month amount (2026-03-29) − 1. Period ending 2026-06-28. Calculation unavailable: missing inputs remain (m). |
| Net income change · 12 months vs previous quarter | -0.01% | Rolling 12-month amount / previous row rolling 12-month amount (2026-03-29) − 1. Period ending 2026-06-28. ($21.04B ÷ $21.04B − 1) × 100 ≈ -0.01% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Revenue · current 12 months | 97.93B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Revenue · rolling 12 months at previous quarter | 96.36B USD | |
| EPS · current 12 months | (m) | Earnings Per Share, Diluted |
| EPS · rolling 12 months at previous quarter | (m) | |
| Net income · current 12 months | 21.04B USD | Net Income (Loss) Attributable to Parent |
| Net income · rolling 12 months at previous quarter | 21.04B USD |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Revenue · current 12 months (USD) | EPS · current 12 months (USD/share) | Net income · current 12 months (USD) | Revenue growth (%) · vs previous quarter | EPS growth (%) · vs previous quarter | Net income growth (%) · vs previous quarter |
|---|---|---|---|---|---|---|
| 2026-06-28 | $97.93B | (m) | $21.04B | 1.63% | (m) | -0.01% |
| 2026-03-29 | $96.36B | (m) | $21.04B | 2.30% | (m) | -21.50% |
| 2025-12-28 | $94.19B | (m) | $26.80B | 2.22% | (m) | 6.71% |
| 2025-09-28 | $92.15B | (m) | $25.12B | 1.68% | (m) | 10.85% |
| 2025-06-29 | $90.63B | (m) | $22.66B | 1.45% | (m) | 3.90% |
| 2025-03-30 | $89.33B | (m) | $21.81B | 0.57% | (m) | 55.05% |
| 2024-12-29 | $88.82B | (m) | $14.07B | 1.28% | (m) | -4.21% |
| 2024-09-29 | $87.70B | (m) | $14.68B | 1.29% | (m) | -61.38% |
| 2024-06-30 | $86.58B | (m) | $38.02B | 1.08% | (m) | -1.19% |
| 2024-03-31 | $85.65B | (m) | $38.48B | 0.57% | (m) | 9.45% |
| 2023-12-31 | $85.16B | (m) | $35.15B | 1.74% | (m) | 1.53% |
| 2023-10-01 | $98.66B | (m) | $34.62B | 0.90% | (m) | 165.24% |
| 2023-07-02 | $97.77B | (m) | $13.05B | 1.57% | (m) | 2.59% |
| 2023-04-02 | $96.26B | (m) | $12.72B | 1.39% | (m) | -29.08% |
| 2023-01-01 | $94.94B | (m) | $17.94B | -1.14% | (m) | -6.35% |
| 2022-10-02 | $96.04B | (m) | $19.16B | 0.47% | (m) | 4.31% |
| 2022-07-03 | $95.59B | (m) | $18.37B | 0.75% | (m) | -7.38% |
| 2022-04-03 | $94.88B | (m) | $19.83B | 1.18% | (m) | -5.02% |
| 2022-01-02 | $93.78B | (m) | $20.88B | 2.55% | (m) | 16.77% |
| 2021-10-03 | $91.45B | (m) | $17.88B | 2.53% | (m) | 0.64% |
| 2021-07-04 | $89.19B | (m) | $17.77B | 5.91% | (m) | 17.55% |
| 2021-04-04 | $84.21B | (m) | $15.12B | 1.97% | (m) | 2.73% |
| 2021-01-03 | $82.58B | (m) | $14.71B | 2.14% | (m) | -13.38% |
| 2020-09-27 | $80.86B | (m) | $16.99B | 0.44% | (m) | 11.86% |
| 2020-06-28 | $80.50B | (m) | $15.19B | -2.69% | (m) | -11.54% |
| 2020-03-29 | $82.73B | (m) | $17.17B | 0.82% | (m) | 13.54% |
| 2019-12-29 | $82.06B | (m) | $15.12B | 0.43% | (m) | 6.84% |
| 2019-09-29 | $81.71B | (m) | $14.15B | 0.47% | (m) | -13.35% |
| 2019-06-30 | $81.33B | (m) | $16.33B | -0.33% | (m) | 11.26% |
| 2019-03-31 | $81.59B | (m) | $14.68B | 0.01% | (m) | -4.04% |
| 2018-12-30 | $81.58B | (m) | $15.30B | 0.24% | (m) | 892.02% |
| 2018-09-30 | (m) | (m) | $1.54B | (m) | (m) | -90.26% |
| 2018-07-01 | (m) | (m) | $1.37B | (m) | (m) | -92.08% |
| 2018-04-01 | (m) | (m) | $1.25B | (m) | (m) | -92.81% |
| 2017-12-31 | (m) | (m) | $1.30B | (m) | (m) | -92.49% |
| 2017-10-01 | (m) | (m) | $15.83B | (m) | (m) | -8.63% |
| 2017-07-02 | (m) | (m) | $16.34B | (m) | (m) | -5.69% |
| 2017-04-02 | (m) | (m) | $16.50B | (m) | (m) | -4.71% |
| 2017-01-01 | (m) | (m) | $16.54B | (m) | (m) | -4.51% |
| 2016-10-02 | (m) | (m) | $15.94B | (m) | (m) | -7.97% |
| 2016-07-03 | (m) | (m) | $15.03B | (m) | (m) | -13.24% |
| 2016-04-03 | (m) | (m) | $15.38B | (m) | (m) | -11.20% |
| 2016-01-03 | (m) | (m) | $15.41B | (m) | (m) | -11.04% |
| 2015-09-27 | (m) | (m) | $14.71B | (m) | (m) | -15.05% |
| 2015-06-28 | (m) | (m) | $16.11B | (m) | (m) | -7.01% |
| 2015-03-29 | (m) | (m) | $15.92B | (m) | (m) | -8.11% |
| 2014-12-28 | (m) | (m) | $16.32B | (m) | (m) | -5.76% |
| 2014-09-28 | (m) | (m) | $17.32B | (m) | (m) | 11.36% |
| 2014-06-29 | (m) | (m) | $15.55B | (m) | (m) | 3.27% |
| 2014-03-30 | (m) | (m) | $15.06B | (m) | (m) | 16.94% |
| 2013-12-29 | (m) | (m) | $13.83B | (m) | (m) | 7.39% |
| 2013-09-29 | (m) | (m) | $12.88B | (m) | (m) | 0.11% |
| 2013-06-30 | (m) | (m) | $12.87B | (m) | (m) | 47.23% |
| 2013-03-31 | (m) | (m) | $10.44B | (m) | (m) | (m) |
| 2012-12-30 | (m) | (m) | $10.85B | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-07-01 | (m) | (m) | $8.74B | (m) | (m) | (m) |
| 2012-04-01 | (m) | (m) | $10.11B | (m) | (m) | (m) |
| 2012-01-01 | (m) | (m) | $9.67B | (m) | (m) | (m) |
| 2011-10-02 | (m) | (m) | $11.40B | (m) | (m) | (m) |
| 2011-07-03 | (m) | (m) | $11.61B | (m) | (m) | (m) |
| 2011-04-03 | (m) | (m) | $12.28B | (m) | (m) | (m) |
| 2011-01-02 | (m) | (m) | $13.33B | (m) | (m) | (m) |
| 2010-10-03 | (m) | (m) | $13.60B | (m) | (m) | (m) |
| 2010-07-04 | (m) | (m) | $13.53B | (m) | (m) | (m) |
| 2010-04-04 | (m) | (m) | $13.29B | (m) | (m) | (m) |
| 2010-01-03 | (m) | (m) | $12.27B | (m) | (m) | (m) |
| 2009-09-27 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-28 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-29 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |